Welcome to our dedicated page for Sigilon Therapeutics news (Ticker: SGTX), a resource for investors and traders seeking the latest updates and insights on Sigilon Therapeutics stock.
Sigilon Therapeutics, Inc. (NASDAQ: SGTX) is a clinical-stage biopharmaceutical company pioneering cell-based therapies for chronic diseases through its Shielded Living Therapeutics™ platform. This page provides investors and medical innovators with essential updates on SGTX's strategic developments, including its acquisition by Eli Lilly to advance diabetes treatment research.
Access timely updates on clinical milestones, partnership expansions, and therapeutic innovations. Key content includes progress reports on SIG-002 for type 1 diabetes, updates on the Lilly collaboration, and analyses of the Afibromer™ biomaterials technology. All press releases are vetted for accuracy and compliance.
Bookmark this page to monitor how Sigilon's acquisition accelerates development of functional cures while maintaining its Cambridge-based research focus. Check regularly for authoritative updates on cell therapy advancements and strategic corporate decisions shaping the future of chronic disease treatment.
Sigilon Therapeutics, a biotechnology company listed on NASDAQ under the symbol SGTX, announced that its CEO, Rogerio Vivaldi, M.D., will present a corporate overview at the Needham Virtual Healthcare Conference on April 20, 2023, at 10:15 a.m. EDT. The presentation will be available via a webcast on the company’s investor website, with a replay accessible for 90 days post-event.
Sigilon is focused on developing functional cures for acute and chronic diseases through its Shielded Living Therapeutics™ platform, utilizing engineered cell-based therapies encapsulated in Afibromer™ biomaterials to prevent immune rejection. The company aims to address various diseases, including diabetes, by providing therapeutic solutions that are currently lacking in patients.
Sigilon Therapeutics reported 2022 Q4 and year-end results, focusing on its lead diabetes program, SIG-002. The company is advancing IND-enabling activities with non-human primate studies expected in H2 2023. SIG-002 has shown efficacy in mouse models for up to 17 weeks. As of December 31, 2022, cash and equivalents were $69.6 million, down from $123.4 million in 2021, primarily due to $51.5 million in operating expenses. R&D expenses decreased to $5.9 million from $14.7 million year-over-year, allowing the anticipated cash runway to extend into 2025. The company looks forward to an IND submission in 2024.
Kytopen, a biotechnology company, has established a Scientific Advisory Board (SAB) to enhance its research and development efforts in gene-modified cell therapies. This newly formed board comprises experts from various fields, aiming to support Kytopen's mission of improving patient access to engineered living medicines. The board will guide current and future innovations, collaborating closely with Kytopen's leadership. Notable members include Cullen Buie, the chair, and Omid Veiseh, a co-founder of Sigilon Therapeutics. Kytopen's proprietary Flowfect® technology aims to streamline the genetic modification process.
Sigilon Therapeutics, Inc. (NASDAQ: SGTX) reported Q3 2022 financial results, highlighting significant progress in its Shielded Living Therapeutics™ platform, with advancements in optimizing cross-linking chemistry and predictive models for pericapsular fibrotic overgrowth (PFO). Cash reserves decreased to $78.3 million from $123.4 million year-over-year. R&D expenses dropped to $8.3 million, reflecting a strategic reprioritization of programs, while net loss decreased to $8.7 million from $20.2 million. The company anticipates initiating IND-enabling studies for its diabetes and MPS-1 programs in H2 2023.
Sigilon Therapeutics (NASDAQ: SGTX) reported its Q2 2022 results on August 4, highlighting ongoing preclinical studies and a focus on its MPS-1 program. The company aims to address pericapsular fibrotic overgrowth impacting hemophilia therapies and plans to report preclinical results in H2 2022. Cash reserves decreased to $88.2 million from $123.4 million, projected to support operations until 2024. R&D expenses fell to $11.9 million, while general and administrative expenses remained steady at $5 million. The net loss decreased to $14.3 million, reflecting strategic cost-saving measures.
